CapsoVision, Inc.
CapsoVision, Inc. (CV) Stock Competitors & Peer Comparison
See (CV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CV | $7.44 | +11.88% | 370.8M | -7.22 | -$1.03 | N/A |
| SIRO | $109.97 | +0.00% | 22B | N/A | N/A | N/A |
| NVST | $25.81 | -0.35% | 4.2B | 92.18 | $0.28 | N/A |
| HIMS | $19.14 | -3.53% | 4.2B | 37.53 | $0.51 | N/A |
| CON | $20.89 | -1.60% | 2.7B | 16.07 | $1.30 | +1.20% |
| BBNX | $9.93 | -0.80% | 440.7M | -5.49 | -$1.81 | N/A |
| NAKA | $0.22 | -3.33% | 82M | -0.84 | -$0.26 | N/A |
| KDLY | $11.30 | +1.16% | 68.1M | -15.48 | -$0.73 | N/A |
| NEUE | $6.75 | +0.00% | 60.9M | -0.38 | -$17.65 | N/A |
| PARK | $17.82 | +2.86% | 34.6M | -98.97 | -$0.18 | N/A |
Stock Comparison
CV vs SIRO Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, CV is priced at $7.44, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas SIRO's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CV is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check SIRO's competition here
CV vs NVST Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, NVST has a market cap of 4.2B. Regarding current trading prices, CV is priced at $7.44, while NVST trades at $25.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas NVST's P/E ratio is 92.18. In terms of profitability, CV's ROE is +1.05%, compared to NVST's ROE of +0.02%. Regarding short-term risk, CV is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NVST's competition here
CV vs HIMS Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, HIMS has a market cap of 4.2B. Regarding current trading prices, CV is priced at $7.44, while HIMS trades at $19.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas HIMS's P/E ratio is 37.53. In terms of profitability, CV's ROE is +1.05%, compared to HIMS's ROE of +0.23%. Regarding short-term risk, CV is more volatile compared to HIMS. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check HIMS's competition here
CV vs CON Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, CON has a market cap of 2.7B. Regarding current trading prices, CV is priced at $7.44, while CON trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas CON's P/E ratio is 16.07. In terms of profitability, CV's ROE is +1.05%, compared to CON's ROE of +0.47%. Regarding short-term risk, CV is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check CON's competition here
CV vs BBNX Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, BBNX has a market cap of 440.7M. Regarding current trading prices, CV is priced at $7.44, while BBNX trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas BBNX's P/E ratio is -5.49. In terms of profitability, CV's ROE is +1.05%, compared to BBNX's ROE of -0.24%. Regarding short-term risk, CV is more volatile compared to BBNX. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check BBNX's competition here
CV vs NAKA Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, NAKA has a market cap of 82M. Regarding current trading prices, CV is priced at $7.44, while NAKA trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas NAKA's P/E ratio is -0.84. In terms of profitability, CV's ROE is +1.05%, compared to NAKA's ROE of -0.21%. Regarding short-term risk, CV is more volatile compared to NAKA. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NAKA's competition here
CV vs KDLY Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CV is priced at $7.44, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CV's ROE is +1.05%, compared to KDLY's ROE of -0.21%. Regarding short-term risk, CV is more volatile compared to KDLY. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check KDLY's competition here
CV vs NEUE Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CV is priced at $7.44, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CV's ROE is +1.05%, compared to NEUE's ROE of +0.09%. Regarding short-term risk, CV is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NEUE's competition here
CV vs PARK Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, PARK has a market cap of 34.6M. Regarding current trading prices, CV is priced at $7.44, while PARK trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas PARK's P/E ratio is -98.97. In terms of profitability, CV's ROE is +1.05%, compared to PARK's ROE of -67.96%. Regarding short-term risk, CV is more volatile compared to PARK. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check PARK's competition here
CV vs BRK Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, CV is priced at $7.44, while BRK trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas BRK's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to BRK's ROE of N/A. Regarding short-term risk, CV is more volatile compared to BRK. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check BRK's competition here
CV vs PFSA Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, PFSA has a market cap of 422K. Regarding current trading prices, CV is priced at $7.44, while PFSA trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas PFSA's P/E ratio is -0.01. In terms of profitability, CV's ROE is +1.05%, compared to PFSA's ROE of +0.90%. Regarding short-term risk, CV is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for CV.Check PFSA's competition here
CV vs MEDC Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CV is priced at $7.44, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas MEDC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to MEDC's ROE of N/A. Regarding short-term risk, CV is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for CV.Check MEDC's competition here
CV vs STJ Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, STJ has a market cap of 0. Regarding current trading prices, CV is priced at $7.44, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas STJ's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to STJ's ROE of +0.21%. Regarding short-term risk, CV is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check STJ's competition here
CV vs SPAN Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, CV is priced at $7.44, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas SPAN's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, CV is more volatile compared to SPAN. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check SPAN's competition here
CV vs EXAC Comparison April 2026
CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CV stands at 370.8M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, CV is priced at $7.44, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CV currently has a P/E ratio of -7.22, whereas EXAC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.05%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, CV is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check EXAC's competition here